CV Outcomes in Diabetes

Risk reduction with antihyperglycaemic therapies


Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).


The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycaemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.


CV specialists are well-positioned to play a key role in managing patients with T2D, including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycaemic agents into routine practice.

Close X
Other videos you might like

Section Advisor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

Recent Videos


ACC 23 Late-breaking Discussion: The COORDINATE-Diabetes Trial

Harriette Van Spall, Neha Pagidipati, Christopher B Granger, et al

Watch time: 17m 32s


Radcliffe & CardioNerds @AHA22: The PROMINENT Trial

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s


AHA 22: BT001 PIVOTAL: nCBT in Pts with Type II Diabetes

Marc P Bonaca,

Watch time: 7m 23s


EASD 22: Efficacy of Ertugliflozin HHF Across the Spectrum of Pre-Trial EF

Ambarish Pandey,

Watch time: 3m 5s


View from the Thoraxcenter – What's Hot at ESC 2022

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 24m 27s


EMPEROR-Preserved: Empagliflozin, Health Status, & QoL in Patients With HFp

Javed Butler,

Watch time: 6m 35s